Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma.

Hassan MS, Williams F, Awasthi N, Schwarz MA, Schwarz RE, Li J, von Holzen U.

Sci Rep. 2019 Nov 26;9(1):17608. doi: 10.1038/s41598-019-54129-7.

2.

A distinct transcriptional profile in response to endothelial monocyte activating polypeptide II is partially mediated by JAK-STAT3 in murine macrophages.

Lee DD, Hochstetler A, Murphy C, Lowe CW, Schwarz MA.

Am J Physiol Cell Physiol. 2019 Sep 1;317(3):C449-C456. doi: 10.1152/ajpcell.00277.2018. Epub 2019 Jun 19.

PMID:
31216192
3.

Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.

Awasthi N, Kronenberger D, Stefaniak A, Hassan MS, von Holzen U, Schwarz MA, Schwarz RE.

Cancer Lett. 2019 Sep 10;459:41-49. doi: 10.1016/j.canlet.2019.05.037. Epub 2019 May 30.

PMID:
31153980
4.

The Meaningfulness of Effect Sizes in Psychological Research: Differences Between Sub-Disciplines and the Impact of Potential Biases.

Schäfer T, Schwarz MA.

Front Psychol. 2019 Apr 11;10:813. doi: 10.3389/fpsyg.2019.00813. eCollection 2019.

5.

Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models of pancreatic cancer.

Awasthi N, Mikels-Vigdal AJ, Stefanutti E, Schwarz MA, Monahan S, Smith V, Schwarz RE.

J Cell Mol Med. 2019 Jun;23(6):3878-3887. doi: 10.1111/jcmm.14242. Epub 2019 Apr 2.

6.

Pancreatic ductal adenocarcinoma cell secreted extracellular vesicles containing ceramide-1-phosphate promote pancreatic cancer stem cell motility.

Kuc N, Doermann A, Shirey C, Lee DD, Lowe CW, Awasthi N, Schwarz RE, Stahelin RV, Schwarz MA.

Biochem Pharmacol. 2018 Oct;156:458-466. doi: 10.1016/j.bcp.2018.09.017. Epub 2018 Sep 15.

7.

Augmentation of Nab-Paclitaxel Chemotherapy Response by Mechanistically Diverse Antiangiogenic Agents in Preclinical Gastric Cancer Models.

Awasthi N, Schwarz MA, Zhang C, Schwarz RE.

Mol Cancer Ther. 2018 Nov;17(11):2353-2364. doi: 10.1158/1535-7163.MCT-18-0489. Epub 2018 Aug 30.

9.

Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma.

Hassan MS, Awasthi N, Li J, Williams F, Schwarz MA, Schwarz RE, von Holzen U.

Transl Oncol. 2018 Apr;11(2):426-435. doi: 10.1016/j.tranon.2018.01.022. Epub 2018 Feb 20.

10.

Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer.

Awasthi N, Monahan S, Stefaniak A, Schwarz MA, Schwarz RE.

Oncotarget. 2017 Dec 25;9(4):5274-5286. doi: 10.18632/oncotarget.23684. eCollection 2018 Jan 12.

11.

α5β1 integrin mediates pulmonary epithelial cyst formation.

Legan SK, Lee DD, Schwarz MA.

Dev Dyn. 2017 Jun;246(6):475-484. doi: 10.1002/dvdy.24502. Epub 2017 Apr 29.

12.

A novel intraperitoneal metastatic xenograft mouse model for survival outcome assessment of esophageal adenocarcinoma.

Hassan MS, Awasthi N, Li J, Schwarz MA, Schwarz RE, von Holzen U.

PLoS One. 2017 Feb 22;12(2):e0171824. doi: 10.1371/journal.pone.0171824. eCollection 2017. Erratum in: PLoS One. 2017 Jun 19;12 (6):e0180146.

13.

Endothelial Monocyte-Activating Polypeptide II Mediates Macrophage Migration in the Development of Hyperoxia-Induced Lung Disease of Prematurity.

Lee DD, Lal CV, Persad EA, Lowe CW, Schwarz AM, Awasthi N, Schwarz RE, Schwarz MA.

Am J Respir Cell Mol Biol. 2016 Oct;55(4):602-612.

14.

MIF-CD74 signaling impedes microglial M1 polarization and facilitates brain tumorigenesis.

Ghoochani A, Schwarz MA, Yakubov E, Engelhorn T, Doerfler A, Buchfelder M, Bucala R, Savaskan NE, Eyüpoglu IY.

Oncogene. 2016 Dec 1;35(48):6246-6261. doi: 10.1038/onc.2016.160. Epub 2016 May 9.

PMID:
27157615
15.

Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models.

Awasthi N, Scire E, Monahan S, Grojean M, Zhang E, Schwarz MA, Schwarz RE.

Oncotarget. 2016 Jul 26;7(30):46988-47001. doi: 10.18632/oncotarget.9029.

16.

Adapted approach to profile genes while reconciling Vegf-a mRNA expression in the developing and injured lung.

Lee DD, Schwarz MA.

Am J Physiol Lung Cell Mol Physiol. 2015 Jun 15;308(12):L1202-11. doi: 10.1152/ajplung.00053.2015. Epub 2015 Apr 10.

17.

The N terminus of pro-endothelial monocyte-activating polypeptide II (EMAP II) regulates its binding with the C terminus, arginyl-tRNA synthetase, and neurofilament light protein.

Xu H, Malinin NL, Awasthi N, Schwarz RE, Schwarz MA.

J Biol Chem. 2015 Apr 10;290(15):9753-66. doi: 10.1074/jbc.M114.630533. Epub 2015 Feb 27.

18.

Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer.

Awasthi N, Hinz S, Brekken RA, Schwarz MA, Schwarz RE.

Cancer Lett. 2015 Mar 1;358(1):59-66. doi: 10.1016/j.canlet.2014.12.027. Epub 2014 Dec 16.

19.

Blockade of EMAP II protects cardiac function after chronic myocardial infarction by inducing angiogenesis.

Yuan C, Yan L, Solanki P, Vatner SF, Vatner DE, Schwarz MA.

J Mol Cell Cardiol. 2015 Feb;79:224-31. doi: 10.1016/j.yjmcc.2014.11.021. Epub 2014 Nov 29.

20.

Cadmium exposure from food: the German LExUKon project.

Schwarz MA, Lindtner O, Blume K, Heinemeyer G, Schneider K.

Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2014;31(6):1038-51. doi: 10.1080/19440049.2014.905711. Epub 2014 Apr 29.

PMID:
24645975
21.

Lead exposure from food: the German LExUKon project.

Schneider K, Schwarz MA, Lindtner O, Blume K, Heinemeyer G.

Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2014;31(6):1052-63. doi: 10.1080/19440049.2014.905875. Epub 2014 May 2.

PMID:
24645773
22.

Vascular mediators in chronic lung disease of infancy: role of endothelial monocyte activating polypeptide II (EMAP II).

Lal CV, Schwarz MA.

Birth Defects Res A Clin Mol Teratol. 2014 Mar;100(3):180-8. doi: 10.1002/bdra.23234. Epub 2014 Mar 12. Review.

23.

Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer.

Awasthi N, Zhang C, Schwarz AM, Hinz S, Schwarz MA, Schwarz RE.

Mol Cancer Ther. 2014 May;13(5):1032-43. doi: 10.1158/1535-7163.MCT-13-0361. Epub 2014 Mar 7.

24.

Semipolar polycyclic aromatic compounds: identification of 15 priority substances and the need for regulatory steps under REACH regulation.

Schwarz MA, Behnke A, Brandt M, Eisenträger A, Hassauer M, Kalberlah F, Seidel A.

Integr Environ Assess Manag. 2014 Jul;10(3):415-28. doi: 10.1002/ieam.1526. Epub 2014 Mar 20.

PMID:
24449130
25.

Dioxin and dl-PCB exposure from food: the German LExUKon project.

Schwarz MA, Lindtner O, Blume K, Heinemeyer G, Schneider K.

Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2014 Apr;31(4):688-702. doi: 10.1080/19440049.2013.878041. Epub 2014 Feb 26.

PMID:
24405321
26.

Definition of K(trans) and FA thresholds for better assessment of experimental glioma using high-field MRI: a feasibility study.

Engelhorn T, Schwarz MA, Hess A, Budinsky L, Pitann P, Eyüpoglu I, Doerfler A.

Clin Neuroradiol. 2014 Dec;24(4):337-45. doi: 10.1007/s00062-013-0257-3. Epub 2013 Dec 18.

PMID:
24346229
27.

The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer.

Zhang CΗ, Awasthi N, Schwarz MA, Schwarz RE.

Int J Oncol. 2013 Nov;43(5):1627-35. doi: 10.3892/ijo.2013.2099. Epub 2013 Sep 13.

28.

Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.

Awasthi N, Zhang C, Schwarz AM, Hinz S, Wang C, Williams NS, Schwarz MA, Schwarz RE.

Carcinogenesis. 2013 Oct;34(10):2361-9. doi: 10.1093/carcin/bgt227. Epub 2013 Jun 26.

29.

Ephrin-B2 reverse signaling increases α5β1 integrin-mediated fibronectin deposition and reduces distal lung compliance.

Bennett KM, Afanador MD, Lal CV, Xu H, Persad E, Legan SK, Chenaux G, Dellinger M, Savani RC, Dravis C, Henkemeyer M, Schwarz MA.

Am J Respir Cell Mol Biol. 2013 Oct;49(4):680-7. doi: 10.1165/rcmb.2013-0002OC.

30.

Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.

Awasthi N, Zhang C, Hinz S, Schwarz MA, Schwarz RE.

J Exp Clin Cancer Res. 2013 Mar 6;32:12. doi: 10.1186/1756-9966-32-12.

31.

MRI assessment of experimental gliomas using 17.6 T.

Schwarz MA, Pham M, Helluy X, Doerfler A, Engelhorn T.

Neuroradiology. 2013 Jun;55(6):709-18. doi: 10.1007/s00234-013-1149-6. Epub 2013 Mar 10.

PMID:
23475161
32.

Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.

Zhang C, Awasthi N, Schwarz MA, Hinz S, Schwarz RE.

PLoS One. 2013;8(2):e58037. doi: 10.1371/journal.pone.0058037. Epub 2013 Feb 27.

33.

Establishing a peritoneal dissemination xenograft mouse model for survival outcome assessment of experimental gastric cancer.

Zhang C, Awasthi N, Schwarz MA, Schwarz RE.

J Surg Res. 2013 Jun 15;182(2):227-34. doi: 10.1016/j.jss.2012.10.052. Epub 2012 Nov 15.

PMID:
23201270
34.

The heart beat does not make us tick: the impacts of heart rate and arousal on time perception.

Schwarz MA, Winkler I, Sedlmeier P.

Atten Percept Psychophys. 2013 Jan;75(1):182-93. doi: 10.3758/s13414-012-0387-8.

PMID:
23143915
35.

BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.

Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE.

Mol Cancer Ther. 2012 Dec;11(12):2644-53. doi: 10.1158/1535-7163.MCT-12-0447. Epub 2012 Oct 9.

36.

Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.

Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE.

PLoS One. 2012;7(6):e38477. doi: 10.1371/journal.pone.0038477. Epub 2012 Jun 18.

37.

Cell proliferation and migration are modulated by Cdk-1-phosphorylated endothelial-monocyte activating polypeptide II.

Schwarz MA, Thornton J, Xu H, Awasthi N, Schwarz RE.

PLoS One. 2012;7(3):e33101. doi: 10.1371/journal.pone.0033101. Epub 2012 Mar 8.

38.

Endothelial-monocyte activating polypeptide II disrupts alveolar epithelial type II to type I cell transdifferentiation.

Chen Y, Legan SK, Mahan A, Thornton J, Xu H, Schwarz MA.

Respir Res. 2012 Jan 3;13:1. doi: 10.1186/1465-9921-13-1.

39.

The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.

Awasthi N, Yen PL, Schwarz MA, Schwarz RE.

J Cell Biochem. 2012 Mar;113(3):784-91. doi: 10.1002/jcb.23405.

PMID:
22020918
40.

Reduction of cerebral infarct size by dronedarone.

Engelhorn T, Schwarz MA, Heusch G, Doerfler A, Schulz R.

Cardiovasc Drugs Ther. 2011 Dec;25(6):523-9. doi: 10.1007/s10557-011-6336-2.

PMID:
21881849
41.

Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.

Awasthi N, Schwarz MA, Schwarz RE.

HPB (Oxford). 2011 Sep;13(9):597-604. doi: 10.1111/j.1477-2574.2011.00333.x. Epub 2011 Jun 7.

42.

Early management of stroke patients in the emergency department.

Woloszyn AV, Schwarz MA.

J Pharm Pract. 2011 Apr;24(2):160-73. doi: 10.1177/0897190011400551.

PMID:
21712211
43.

Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure.

Tentzeris I, Jarai R, Farhan S, Perkmann T, Schwarz MA, Jakl G, Wojta J, Huber K.

Eur J Heart Fail. 2011 Jul;13(7):726-33. doi: 10.1093/eurjhf/hfr049. Epub 2011 May 26.

44.

Concordance of butyrylcholinesterase phenotype with genotype: implications for biochemical reporting.

Parnas ML, Procter M, Schwarz MA, Mao R, Grenache DG.

Am J Clin Pathol. 2011 Feb;135(2):271-6. doi: 10.1309/AJCPPI5KLINEKH7A.

PMID:
21228368
45.

Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer.

Awasthi N, Kirane A, Schwarz MA, Toombs JE, Brekken RA, Schwarz RE.

BMC Cancer. 2011 Jan 12;11:15. doi: 10.1186/1471-2407-11-15.

46.

Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy.

Awasthi N, Schwarz MA, Schwarz RE.

Cancer Chemother Pharmacol. 2011 Sep;68(3):571-82. doi: 10.1007/s00280-010-1514-7. Epub 2010 Nov 26.

PMID:
21110024
47.

Oseltamivir-resistant influenza A 2009 H1N1 virus in immunocompromised patients.

Couturier BA, Bender JM, Schwarz MA, Pavia AT, Hanson KE, She RC.

Influenza Other Respir Viruses. 2010 Jul;4(4):199-204. doi: 10.1111/j.1750-2659.2010.00144.x.

48.

Lung self-assembly is modulated by tissue surface tensions.

Schwarz MA, Zheng H, Legan S, Foty RA.

Am J Respir Cell Mol Biol. 2011 May;44(5):682-91. doi: 10.1165/rcmb.2009-0309OC. Epub 2010 Jul 8.

49.

Proteasome inhibition enhances antitumour effects of gemcitabine in experimental pancreatic cancer.

Awasthi N, Schwarz MA, Schwarz RE.

HPB (Oxford). 2009 Nov;11(7):600-5. doi: 10.1111/j.1477-2574.2009.00109.x.

50.

Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer.

Awasthi N, Schwarz MA, Schwarz RE.

Cancer Biol Ther. 2010 Jul 1;10(1):99-107. Epub 2010 Jul 26.

PMID:
20495354

Supplemental Content

Loading ...
Support Center